N-isopropyl-2-(p-nitrophenoxy)ethylamine | 60814-19-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-isopropyl-2-(p-nitrophenoxy)ethylamine
• 英文别名: N-(1-methylethyl)-2-(4-nitrophenoxy)ethanamine；isopropyl-[2-(4-nitro-phenoxy)-ethyl]-amine；isopropyl-[2-(4-nitrophenoxy)ethyl]amine；N-Isopropyl-2-(4-nitrophenoxy)-ethanamin；N-Isopropyl-2-(p-nitrophenoxy)-ethylamin；N-Isopropyl-2-p-nitrophenoxyaethylamin；N-[2-(4-nitrophenoxy)ethyl]propan-2-amine
• CAS: 60814-19-9
• 化学式: C₁₁H₁₆N₂O₃
• mdl: MFCD11200197
• 分子量: 224.26
• InChiKey: FSFWIEYKZYDEAJ-UHFFFAOYSA-N

物化性质

• 熔点：
  9-10 °C
• 沸点：
  351.6±22.0 °C(Predicted)
• 密度：
  1.118±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  67.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-isopropyl-2-(p-nitrophenoxy)ethylamine 在 sodium hydroxide 作用下， 以 水 为溶剂， 生成 2-[Isopropyl-(4-nitro-phenyl)-amino]-ethanol
  参考文献：
  名称：

  Knipe, Anthony C.; Sridhar, Narayan; Lound-Keast, Joseph, Journal of the Chemical Society. Perkin transactions II, 1984, p. 1893 - 1900

  摘要：

  DOI：
• 作为产物：
  描述：

  对氟硝基苯 在 sodium hydride 作用下， 以 二甲基亚砜 为溶剂， 反应 0.5h， 生成 N-isopropyl-2-(p-nitrophenoxy)ethylamine
  参考文献：
  名称：

  [EN] 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES
  [FR] DERIVES DE 2-AMINO-4-HYDROXY-5-PYRIMIDINOCARBOXAMIDE ET COMPOSES ASSOCIES SERVANT D'INHIBITEURS DE L'ACTIVATION DES LYMPHOCYTES T POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES

  摘要：

  本发明涉及嘧啶或吡啶甲酰胺或其药用可接受的盐。还包括一种治疗炎症、抑制T细胞激活和增殖、关节炎、类风湿性关节炎、银屑病关节炎、骨关节炎、器官移植、急性移植或异体移植或同种异体移植排斥、移植耐受性诱导、缺血或再灌注损伤、心肌梗死、中风、多发性硬化症、炎症性肠病，包括溃疡性结肠炎、克罗恩病、狼疮、接触超敏反应、迟发型超敏反应和谷蛋白敏感性肠病、1型糖尿病、银屑病、接触性皮炎、桥本甲状腺炎、舍格伦综合征、自身免疫性甲状腺功能亢进、阿狄森病、自身免疫多腺体病、自身免疫性脱发、恶性贫血、白癜风、自身免疫性垂体功能减退、吉兰-巴雷综合征、肾小球肾炎、血清病、荨麻疹、过敏性疾病、哮喘、花粉症、过敏性鼻炎、硬皮病、真菌病、皮肌炎、斑秃、慢性日光性皮炎、湿疹、贝赫切特病、掌跖脓疱病、脓皮病、塞扎里综合征、特应性皮炎、系统性硬化病、硬皮病、特应性皮炎、结肠癌或胸腺瘤的方法，包括施用如上所述的化合物的治疗有效量。

  公开号：

  WO2005009443A1

文献信息

• DIAMINOTHIAZOLES
  申请人：——

  公开号：US20040006058A1

  公开（公告）日：2004-01-08

  The present invention is directed to novel diaminothiazoles of formula 1 These compounds inhibit cyclin-dependent kinase 4 (Cdk4) and are selective against Cdk2 and Cdk1. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment 6r control of breast, lung and colon and prostate tumors.

  本发明涉及一种新型的formula1的二氨基噻唑化合物。这些化合物抑制细胞周期依赖性激酶4（Cdk4），并且对Cdk2和Cdk1具有选择性。这些化合物及其药学上可接受的盐和酯具有抗增殖活性，并且在治疗或控制癌症，特别是固体肿瘤方面具有用途。本发明还涉及含有这些化合物的药物组合物，以及治疗或控制癌症的方法，尤其是治疗或控制乳腺、肺部、结肠和前列腺肿瘤的方法。
• [EN] 2-AMINOPYRIMIDINE AND 2-AMINOPYRIDINE-4-CARBAMATES FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES<br/>[FR] 2-AMINOPYRIMIDINE ET 2-AMINOPYRIDINE-4-CARBAMATES DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES AUTO-IMMUNES
  申请人：AMGEN INC

  公开号：WO2005009978A1

  公开（公告）日：2005-02-03

  The present invention relates to pyrimidine or pyridine carbamate compounds having the general Formula (1) and pharmaceutically acceptable salts or derivatives thereof. Also included are methods of treatment of various diseases and conditions, including inflammation, inhibition of T cell activation and proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma, thymoma, just to name a few, in a mammal, the methods comprising administering a therapeutically-effective amount a compound of Formula I, or a salt or derivative form thereof, as described above.

  本发明涉及具有通用式（1）的嘧啶或吡啶羰酸酯化合物及其药用可接受的盐或衍生物。还包括治疗各种疾病和症状的方法，包括炎症、抑制T细胞激活和增殖、关节炎、器官移植、缺血或再灌注损伤、心肌梗死、中风、多发性硬化、炎症性肠病、克罗恩病、狼疮、过敏、1型糖尿病、牛皮癣、皮炎、桥本氏甲状腺炎、干燥综合征、自身免疫性甲状腺功能亢进症、艾迪生病、自身免疫疾病、肾小球肾炎、过敏性疾病、哮喘、花粉症、湿疹、癌症、结肠癌、胸腺瘤等，在哺乳动物中的方法，包括给予通用式I的化合物的治疗有效量，或如上所述的盐或衍生物形式。
• [EN] SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSES HETEROCYCLIQUES SUBSTITUES ET LEURS METHODES D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2005021551A1

  公开（公告）日：2005-03-10

  The present invention relates to tetracyclic pyrimidines or pyridines or pharmaceutically-acceptable salts or derivatives thereof. Also included are methods of use of the tetracyclic pyrimidines or pyridines including use related to treating inflammation, inhibiting T cell activation and proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease and many other related disorders in a subject, the methods comprising administering a therapeutically-effective amount a compound as described above to the subject.

  本发明涉及四环嘧啶或吡啶或其药用盐或衍生物。还包括使用四环嘧啶或吡啶的方法，包括用于治疗炎症、抑制T细胞激活和增殖、关节炎、器官移植、缺血再灌注损伤、心肌梗死、中风、多发性硬化、炎症性肠病和其他相关疾病的方法，在这些方法中向受试者施用上述化合物的治疗有效量。
• Substituted heterocyclic compounds and methods of use
  申请人：Elbaum Daniel

  公开号：US20050107374A1

  公开（公告）日：2005-05-19

  The present invention relates to hydroxybenzimidazole pyrimidines or pyridines or pharmaceutically-acceptable salts thereof. Also included is a method of treatment of inflammation, inhibition of T cell activation and proliferation, arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, organ transplant, acute transplant or heterograft or homograft rejection, transplantation tolerance induction, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, including ulcerative colitis, Crohn's disease, lupus, contact hypersensitivity, delayed-type hypersensitivity, and gluten-sensitive enteropathy, type 1 diabetes, psoriasis, contact dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune polyglandular disease, autoimmune alopecia, pernicious anemia, vitiligo, autoimmune hypopituatarism, Guillain-Barre syndrome, glomerulonephritis, serum sickness, uticaria, allergic diseases, asthma, hayfever, allergic rhinitis, scleracielma, mycosis fungoides, dermatomyositis, alopecia areata, chronic actinic dermatitis, eczema, Behcet's disease, Pustulosis palmoplanteris, Pyoderma gangrenum, Sezary's syndrome, atopic dermatitis, systemic schlerosis, morphea, atopic dermatitis, colon carcinoma or thymoma in a mammal comprising administering a therapeutically-effective amount a compound as described above.

  本发明涉及羟基苯并咪唑嘧啶或吡啶或其药学上可接受的盐。还包括一种治疗炎症、抑制T细胞活化和增殖、关节炎、类风湿性关节炎、银屑病性关节炎、骨关节炎、器官移植、急性移植或异种移植或同种移植排斥、移植耐受诱导、缺血或再灌注损伤、心肌梗死、中风、多发性硬化症、炎症性肠病，包括溃疡性结肠炎、克罗恩病、狼疮、接触性超敏反应、迟发型超敏反应和对谷蛋白敏感性肠病、1型糖尿病、银屑病、接触性皮炎、桥本氏甲状腺炎、干燥综合征、自身免疫性甲状腺功能亢进症、阿迪森病、自身免疫性多腺体病、自身免疫性脱发、恶性贫血、白癜风、自身免疫性下丘脑功能减退症、格林-巴利综合征、肾小球肾炎、血清病、荨麻疹、过敏性疾病、哮喘、花粉热、过敏性鼻炎、硬皮病、真菌病、皮肌炎、斑秃、慢性光化性皮炎、湿疹、Behcet病、掌跖角化症、脓疱性荨麻疹、塞萨里综合征、特应性皮炎、系统性硬化症、硬皮病、特应性皮炎、哺乳动物的结肠癌或胸腺瘤，包括上述化合物的治疗有效量的给药方法。
• Diaminothiazoles
  申请人：Hoffmann-La Roches

  公开号：US06818663B2

  公开（公告）日：2004-11-16

  The present invention is directed to novel diaminothiazoles of formula These compounds inhibit cyclin-dependent kinase 4 (Cdk4) and are selective against Cdk2 and Cdk1. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung and colon and prostate tumors.

  本发明涉及一种新型二氨基噻唑的公式，这些化合物抑制细胞周期蛋白依赖性激酶4（Cdk4），并且对Cdk2和Cdk1具有选择性。这些化合物及其药学上可接受的盐和酯具有抗增殖活性，并且在治疗或控制癌症，特别是实体肿瘤方面非常有用。本发明还涉及含有这些化合物的制药组合物以及治疗或控制癌症的方法，尤其是治疗或控制乳腺、肺、结肠和前列腺肿瘤的方法。